PBMC humanized mice are effective model animals for infectious diseases, GvHD, and immuno-oncology. In case of stimulation by mouse xenoantigens, T cells in human-derived PBMCs can proliferate, while other types of cells maintain a low content or die prematurely. The human-derived cells in PBMC humanized mice are mainly T cells, which are suitable for various studies that require T cell immune responses. However, T cells also over-immunize the recipient mice and then trigger graft-versus-host disease (GvHD), which may cause the mice to die after a few weeks. Therefore, PBMC humanized mice have a short window period for tests and are only suitable for short-term studies. The PBMC humanized mice are constructed on the basis of M-NSG-B2m mice but experience the elimination of the B2M β-subunit gene of the MHC class I molecule, which will delay the attack of human immune cells against the host and extend the test window period.
Figure 1. Preparation process of M-NSG mice transplanted with human-derived PBMCs.
Figure 2. Human-derived CD45+ cell content in peripheral blood of M-NSG mice transplanted with human-derived PBMCs and body weight changes of mice.
Six groups of M-NSG mice were injected with PBMCs from six donors via tail vein, respectively. The overall trend of increased proportion of human-derived CD45+ cells could be detected, with differences in chimerism proportion changes but overall trend as expected. Relatively stable changes in body weight were observed in the mice.
Figure 3. Anti-tumor efficacy validation in Hu-PBMC H929 tumor-bearing mouse model
Figure 4. Anti-tumor efficacy validation in Hu-PBMC A431 tumor-bearing mouse model
Hematological disease study
Infectious disease study
Study on drug targets without cross reactions
If you need to place an order, please feel free to contact us: 400-728-0660 or email@example.com.
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.Learn more
After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.Learn more